Show simple item record

dc.contributor.authorHenriksson, Gunnel
dc.contributor.authorBredberg, Johan Per Ivar B
dc.contributor.authorWullt, Marlene
dc.contributor.authorLyrenäs, Ebbe
dc.contributor.authorHindorf, Ulf
dc.contributor.authorOhlsson, Björn
dc.contributor.authorGrip, Olof
dc.date.accessioned2019-09-02T14:40:02Z
dc.date.available2019-09-02T14:40:02Z
dc.date.created2019-05-02T12:54:42Z
dc.date.issued2019
dc.identifier.citationJournal of Gastroenterology and Hepatology Open (JGH Open). 2019, 3 (2), 154-158.nb_NO
dc.identifier.issn2397-9070
dc.identifier.urihttp://hdl.handle.net/11250/2612099
dc.description.abstractBackground and Aim: An abnormal immune response to intestinal bacteria has been observed in Crohn’s disease (CD). Clostridium difficile infection incidence and severity are increased in CD, but reports on the humoral response have provided conflicting results. We aimed to shed light on the possible role of C. difficile in CD pathogenesis by paying attention to the influence of immunomodulatory treatment on the humoral response. Methods: A total of 71 consecutive outpatients with CD, 67 with ulcerative colitis (UC), and 121 healthy controls were analyzed for serum IgA and IgG to C. difficile toxins A and B. Results: IgA levels were similar in all study groups. IgG to toxin A was increased similarly in CD and UC (P = 0.02 for both). In contrast, IgG to toxin B was elevated only in CD patients not receiving disease-modifying anti-inflammatory bowel disease drugs (DMAID) (n = 16) (P = 0.0001), while the CD medication subgroup (n = 47) had a level similar to healthy controls. The UC results were not influenced by DMAID treatment. Conclusion: Our findings add support to the idea of a disturbed interaction between intestinal cells and the microbiota being part of the CD disease mechanism. An abnormal immune response to C. difficile toxin B may be a critical component of this interaction.nb_NO
dc.language.isoengnb_NO
dc.publisherWileynb_NO
dc.rightsNavngivelse-Ikkekommersiell 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/deed.no*
dc.subjectClostridium difficilenb_NO
dc.subjectClostridium difficile toxin Bnb_NO
dc.subjectCrohn’s diseasenb_NO
dc.subjecthumoral responsenb_NO
dc.subjectinflammatory bowel diseasenb_NO
dc.titleHumoral response to Clostridium difficile in inflammatory bowel disease, including correlation with immunomodulatory treatmentnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.subject.nsiVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750nb_NO
dc.subject.nsiVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Gasteroenterologi: 773nb_NO
dc.source.pagenumber154-158nb_NO
dc.source.volume3nb_NO
dc.source.journalJournal of Gastroenterology and Hepatology Open (JGH Open)nb_NO
dc.source.issue2nb_NO
dc.identifier.doi10.1002/jgh3.12122
dc.identifier.cristin1695143
cristin.unitcode224,30,0,0
cristin.unitnameAvdeling for lærerutdanning
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse-Ikkekommersiell 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse-Ikkekommersiell 4.0 Internasjonal